Skip to content
Homepage
Author:
UroGen Pharma Ltd.
Posted Date:
May 15, 2026
UroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBC
UroGen Pharma Ltd.
May 15, 2026
ZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION Trial
UroGen Pharma Ltd.
May 13, 2026
ZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION Trial
UroGen Pharma Ltd.
May 13, 2026
UroGen Pharma to Present at Upcoming Investor Conferences
UroGen Pharma Ltd.
May 7, 2026
UroGen Reports ZUSDURI™ Revenue More Than Doubled Quarter-over-Quarter and Provides First Quarter 2026 Financial Results and Highlights
UroGen Pharma Ltd.
May 7, 2026
UroGen Pharma to Report First Quarter 2026 Financial Results on Wednesday, May 6th, 2026
UroGen Pharma Ltd.
April 29, 2026
UroGen Launches LG-UTUC Luminaries Initiative Recognizing Excellence and Leadership in Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer
UroGen Pharma Ltd.
April 8, 2026
Journal of Urology Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURI
UroGen Pharma Ltd.
March 30, 2026
Journal of Urology Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURI
UroGen Pharma Ltd.
March 30, 2026
UroGen Applauds BCAN’s New Faces of Bladder Cancer Report Highlighting Recurrence Burden and Fear of Recurrence
UroGen Pharma Ltd.
March 13, 2026
Prev
1
2
3
Next
